Letter by Lensen et al Regarding Article, "Anti-Tumor Necrosis Factor- Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis"

被引：1
|
作者：
Lensen, Karel-Jan D. F. [1 ]
van Sijl, Alper M. [1 ]
Smulders, Yvo M. [1 ]
机构：
[1] Vrije Univ Amsterdam Med Ctr, Dept Internal Med, Inst Cardiovasc Res, Amsterdam, Netherlands
来源：
CIRCULATION | 2013年 / 128卷 / 01期
关键词：
F-18-FDG PET; ATHEROSCLEROSIS;
D O I：
10.1161/CIRCULATIONAHA.112.000549
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E10 / E10
页数：1
相关论文
共 50 条
  • [31] Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis
    Braun-Moscovici, Y
    Markovits, D
    Zinder, O
    Schapira, D
    Rozin, A
    Ehrenburg, M
    Dain, L
    Hoffer, E
    Nahir, AM
    Balbir-Gurman, A
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (03) : 497 - 500
  • [32] Reply to the letter by Bruno Seriolo about the original article entitled "Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis"
    Soubrier, Martin
    JOINT BONE SPINE, 2009, 76 (01) : 118 - 118
  • [33] Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-α antibody therapy
    Sekigawa, I.
    Yanagida, M.
    Iwabuchi, K.
    Kaneda, K.
    Kaneko, H.
    Takasaki, Y.
    Jung, G.
    Sone, S.
    Tanaka, Y.
    Ogawa, H.
    Takamori, K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (02) : 261 - 267
  • [34] Erratum to: Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients
    Gianluigi Mazzoccoli
    Incoronata Notarsanto
    Gennaro Davide de Pinto
    Mariangela Pia Dagostino
    Angelo De Cata
    Giuseppe D’Alessandro
    Roberto Tarquini
    Gianluigi Vendemiale
    Internal and Emergency Medicine, 2011, 6 : 97 - 97
  • [35] Requirement of methotrexate in combination with anti-tumor necrosis factor-α therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis
    Matsuno, Hiroaki
    Yoshida, Kaoru
    Ochiai, Akira
    Okamoto, Masahiro
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (12) : 2326 - 2333
  • [36] Development of Rheumatoid Nodules after Anti-Tumor Necrosis Factor-α Treatment with Adalimumab for Rheumatoid Arthritis
    Shin, Sungsik
    Chung, Kee Yang
    Kim, Dae Suk
    ANNALS OF DERMATOLOGY, 2016, 28 (03) : 402 - 403
  • [37] Anti-Tumor Necrosis Factor Alpha Therapy and Periodontal Inflammation in Rheumatoid Arthritis A clinical and biochemical approach
    Ancuta, Codrina
    Ancuta, Eugen
    Chirieac, Rodica
    Antohe, Magda
    Iordache, Cristina
    REVISTA DE CHIMIE, 2017, 68 (02): : 369 - 372
  • [38] Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone
    Edwards, Carl K., III
    Green, Julie S.
    Volk, Hans-Dieter
    Schiff, Michael
    Kotzin, Brian L.
    Mitsuya, Hiroaki
    Kawaguchi, Tatsuya
    Sakata, Ken-Mei
    Cheronis, John
    Trollinger, David
    Bankaitis-Davis, Danute
    Dinarello, Charles A.
    Norris, David A.
    Bevilacqua, Michael P.
    Fujita, Mayumi
    Burmester, Gerd-Rudiger
    FRONTIERS IN IMMUNOLOGY, 2012, 3
  • [39] An alternative, autonomic rationale for decreased risk of myocardial infarction in patients with rheumatoid arthritis responsive to anti-tumor necrosis factor therapy: comment on the article by Dixon et al - Reply
    Dixon, W. G.
    Hyrich, K. L.
    Symmons, D. P. M.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (06): : 1886 - 1886
  • [40] Potentiated Antibodies to Tumor Necrosis Factor-α in the Therapy of Patients with Rheumatoid Arthritis
    L. V. Kozlovskaya
    N. A. Mukhin
    V. V. Rameev
    I. A. Sarkisova
    O. I. Epstein
    Bulletin of Experimental Biology and Medicine, 2003, 135 (Suppl 7) : 152 - 154
12345